Browse courses by:
By: Carl Regillo, MD; W. Lloyd Clark, MD
This course has expired. You can still review the content but course credit is no longer available.
The increasing number of new patients with CNV and neovascular AMD presenting to retina specialists on top of the already large and active treatment population has created a desire among clinicians to reduce treatment burden. Recent studies suggest that long-term treatment outcomes are not necessarily sustained over time. This could be a result of under treatment, disease progression, or even tachyphylaxis to the anti-VEGF drug.
Until more is known about how neovascular AMD progresses and what the best treatment algorithms are, retina specialists will need to stay abreast of the latest study findings in order to continue to deliver the best patient care.
Supported by an educational grant from Regeneron Pharmaceuticals.
Upon completion of this activity, participants will be better able to:
Accreditation and Designation Statement
ACCREDITATION STATEMENT
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA CREDIT DESIGNATION STATEMENT
Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following faculty members have the following financial relationships with commercial interests:
•Lloyd Clark, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Bayer Pharmaceuticals; Genentech, Inc; Ohr Pharmaceutical, Inc.; Regeneron Pharmaceuticals, Inc.; and Santen Pharmaceutical Co., Ltd. Grant/Research Support: Allergan, Inc.; Genentech, Inc and Regeneron Pharmaceuticals, Inc.
•Carl Regillo, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan, Inc.; Genentech, Inc; Iconic Therapeutics; and Notal Vision. Grant/Research Support: Alcon; Allergan, Inc.; Genentech, Inc; GlaxoSmithKline; Iconic Therapeutics; Novartis; and Regeneron Pharmaceuticals, Inc.
Editorial Support Disclosure
•Cheryl Cavanaugh, MS, Evolve Medical Education LLC and Michelle Dalton, Writer; have no real or apparent conflicts of interest to report.
•Rishi P. Singh, MD, Peer Reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan Plc; Carl Zeiss Meditec; Genentech, Inc; Optos; Regeneron Pharmaceuticals, Inc; and Shire Plc. Grant/Research Support: Alcon; Apellis Pharmaceuticals; Genentech, Inc; and Regeneron Pharmaceuticals, Inc.